When should Basaglar (insulin glargine) be administered twice daily instead of once daily in an adult with type 2 diabetes?

When to Use Basaglar Twice Daily

Basaglar (insulin glargine) is FDA-approved and designed for once-daily administration, and twice-daily dosing is not a standard or recommended approach for this formulation in adults with type 2 diabetes. 1

Standard Dosing Protocol

According to the FDA label, Basaglar should be:

• Administered subcutaneously once daily at any time of day, but at the same time every day 1
• Not split into twice-daily doses as part of routine management

The pharmacokinetic profile of insulin glargine U100 (Basaglar) is specifically engineered for 24-hour coverage with once-daily administration 1.

When Once-Daily Dosing Fails

If glycemic targets are not achieved with once-daily Basaglar, the evidence-based approach is not to split the dose, but rather to:

Intensification Strategy (in order of preference):

1. Add prandial insulin - Start with a single injection of rapid-acting insulin before the largest meal (4 units or 10% of basal dose), then advance to multiple prandial doses if needed 2, 3

2. Switch to twice-daily premixed insulin - Discontinue Basaglar and transition to 70/30 formulations given before breakfast and dinner 4

3. Add a GLP-1 receptor agonist - Consider fixed-ratio combinations or separate GLP-1 RA therapy 2, 4

Specific Thresholds for Intensification:

• Basal insulin dose exceeds 0.5 units/kg/day without achieving target 2
• Fasting glucose controlled but A1C remains above goal 2
• BeAM score (bedtime minus pre-breakfast glucose) >50 mg/dL 2

The Twice-Daily Exception: NPH or Detemir

If twice-daily basal insulin is clinically indicated, the appropriate choice is NOT Basaglar but rather:

• NPH insulin (given twice daily) 5
• Insulin detemir (can be given once or twice daily) 5

The 2012 Endocrine Society guideline specifically states: "Give basal insulin once (glargine/detemir) or twice (detemir/NPH) daily" 5, clearly distinguishing that glargine (Basaglar) is a once-daily formulation.

Limited Research Context

While isolated case reports 6 and one small ICU study 7 have explored twice-daily glargine dosing, these represent:

• Off-label use not supported by FDA labeling 1
• Special circumstances (critical illness, refractory hypoglycemia) that are exceptions, not routine practice
• No guideline endorsement from major diabetes organizations 2

Critical Pitfall to Avoid

Do not split Basaglar into twice-daily dosing as a routine strategy for inadequate glycemic control. This approach:

• Lacks guideline support
• Contradicts FDA labeling 1
• Ignores more effective intensification strategies (adding prandial insulin or GLP-1 RA) 2
• May increase injection burden without proven benefit over proper intensification

The Correct Algorithm:

1. Optimize once-daily Basaglar dose (titrate to fasting glucose <110 mg/dL) 2
2. If A1C remains above goal despite adequate fasting control → add prandial insulin at largest meal 2, 3
3. If unable/unwilling to do multiple injections → switch to twice-daily premixed insulin 4
4. Consider GLP-1 RA addition for weight concerns or CV benefits 2, 4

Bottom line: Basaglar is a once-daily insulin. If once-daily isn't working, intensify the regimen appropriately rather than splitting the dose.